PolyPid Ltd. announced on June 17, 2025, that it secured $26.7 million in aggregate gross proceeds through the immediate exercise of existing warrants. These warrants were originally issued in January 2024 and December 2024.
The funding was obtained through new agreements with certain warrant holders for the exercise of 7,626,514 ordinary shares at a price of $3.50 per share. In consideration for the immediate exercise, PolyPid will issue 7,626,514 new unregistered warrants, exercisable at $4.50 per share for a term of two years.
This additional funding is anticipated to extend PolyPid’s cash runway beyond the expected FDA approval of D-PLEX100. The net proceeds from this transaction, expected to close around June 18, 2025, will be allocated towards the New Drug Application (NDA) submission, launch preparations, working capital, and general corporate purposes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.